Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial

被引：1

作者：

Qin, S. ^{[1
]}

Bi, F. ^{[2
]}

Xu, J. ^{[3
]}

Du, C. ^{[4
]}

Fan, Q. ^{[5
]}

Zhang, L. ^{[6
]}

Tao, M. ^{[7
]}

Jiang, D. ^{[8
]}

Wang, S. ^{[9
]}

Chen, Y. ^{[10
]}

Sheng, J. ^{[11
]}

Zhuang, X. ^{[12
]}

Wu, J. ^{[13
]}

Lv, B. ^{[14
]}

机构：

[1] Jinling Hosp, PLA Canc Ctr, Nanjing, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Med Oncol, Chengdu, Peoples R China

[3] Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Med Oncol, Beijing, Peoples R China

[4] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China

[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China

[6] Xuzhou Med Univ, Affiliated Hosp, Dept Radiotherapy, Xuzhou, Jiangsu, Peoples R China

[7] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China

[8] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China

[9] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China

[10] Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect & Liver Dis, Wenzhou, Peoples R China

[11] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Infect Dis, Hangzhou, Peoples R China

[12] Shantou Univ, Med Coll, Canc Hosp, Dept Intervent Therapy, Shantou, Peoples R China

[13] First Peoples Hosp Changzhou, Dept Oncol, Changzhou, Jiangsu, Peoples R China

[14] Suzhou Zelgen Biopharmaceut Co Ltd, Suzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.04.168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-86

引用

页码：S117 / S118

页数：2

共 50 条

[1] Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial
Qin, S.
Bi, F.
Cui, C.
Zhu, B.
Wu, J.
Xin, X.
Wang, J.
Shan, J.
Chen, J.
Zheng, Z.
Xu, L.
Wen, X.
You, Z.
Ren, Z.
Wu, X.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S688 - S688
[2] Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Qin, Shukui
Bi, Feng
Gu, Shanzhi
Bai, Yuxian
Chen, Zhendong
Wang, Zishu
Ying, Jieer
Lu, Yinying
Meng, Zhiqiang
Pan, Hongming
Yang, Ping
Zhang, Helong
Chen, Xi
Xu, Aibing
Cui, Chengxu
Zhu, Bo
Wu, Jian
Xin, Xiaoli
Wang, Jufeng
Shan, Jinlu
Chen, Junhui
Zheng, Zhendong
Xu, Li
Wen, Xiaoyu
You, Zhenyu
Ren, Zhenggang
Liu, Xiufeng
Qiu, Meng
Wu, Liqing
Chen, Feng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3002 - +
[3] Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Bi, Feng
Qin, Shukui
Gu, Shanzhi
Bai, Yuxian
Chen, Zhendong
Wang, Zishu
Ying, Jieer
Lu, Yinying
Meng, Zhiqiang
Pan, Hongming
Yang, Ping
Zhang, Helong
Chen, Xi
Xu, Aibing
Liu, Xiufeng
Meng, Qiu
Wu, Liqing
Chen, Feng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.
Qin, Shukui
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Yau, Thomas
Park, Joong-Won
Finn, Richard S.
Cheng, Ann-Lii
Mathurin, Philippe
Edeline, Julien
Kudo, Masatoshi
Harding, James J.
Merle, Philippe
Rosmorduc, Olivier
Wyrwicz, Lucjan
Schott, Eckart
Choo, Su Pin
Kelley, Robin Kate
Sieghart, Wolfgang
Assenat, Eric
Zaucha, Renata
Furuse, Junji
Abou-Alfa, Ghassan K.
El-Khoueiry, Anthony B.
Melero, Ignacio
Begic, Damir
Chen, Gong
Neely, Jaclyn
Wisniewski, Tami
Tschaika, Marina
Sangro, Bruno
[J]. LANCET ONCOLOGY, 2022, 23 (01): : 77 - 90
[6] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Faivre, Sandrine
Raymond, Eric
Boucher, Eveline
Douillard, Jean
Lim, Ho Y.
Kim, Jun S.
Zappa, Magaly
Lanzalone, Silvana
Lin, Xun
DePrimo, Samuel
Harmon, Charles
Ruiz-Garcia, Ana
Lechuga, Maria J.
Cheng, Ann Lii
[J]. LANCET ONCOLOGY, 2009, 10 (08): : 794 - 800
[7] Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
Qin, Shukui
Ren, Zhenggang
Meng, Zhiqiang
Chen, Zhendong
Chai, Xiaoli
Xiong, Jianping
Bai, Yuxian
Yang, Lin
Zhu, Hong
Fang, Weijia
Lin, Xiaoyan
Chen, Xiaoming
Li, Enxiao
Wang, Linna
Chen, Chunxia
Zou, Jianjun
[J]. LANCET ONCOLOGY, 2020, 21 (04): : 571 - 580
[8] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
Palmer, Daniel H.
Peck-Radosavljevic, Markus
Ma, Yuk Ting
Graham, Janet
Fartoux, Laetitia
Hubner, Richard
Loembe, Arsene Bienvenu
Studeny, Matus
Hocke, Julia
Meyer, Tim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[9] Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Cheng, Ann-Lii
Thongprasert, Sumitra
Lim, Ho Yeong
Sukeepaisarnjaroen, Wattana
Yang, Tsai-Shen
Wu, Cheng-Chung
Chao, Yee
Chan, Stephen L.
Kudo, Masatoshi
Ikeda, Masafumi
Kang, Yoon-Koo
Pan, Hongming
Numata, Kazushi
Han, Guohong
Balsara, Binaifer
Zhang, Yong
Rodriguez, Ana-Marie
Zhang, Yi
Wang, Yongyu
Poon, Ronnie T. P.
[J]. HEPATOLOGY, 2016, 64 (03) : 774 - 784
[10] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
D. H. Palmer
Y. T. Ma
M. Peck-Radosavljevic
P. Ross
J. Graham
L. Fartoux
A. Deptala
M. Studeny
D. Schnell
J. Hocke
A-B. Loembé
T. Meyer
[J]. British Journal of Cancer, 2018, 118 : 1162 - 1168

← 1 2 3 4 5 →